For the quarter ended December 2023, Viatris (VTRS) reported revenue of $3.84 billion, down 1% over the same period last year. EPS came in at $0.61, compared to $0.69 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.92 billion, representing a surprise of -2.22%. The company delivered an EPS surprise of -8.96%, with the consensus EPS estimate being $0.67.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

PITTSBURGH, Feb. 28, 2024 /PRNewswire/ -- Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1]   Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of $54.7 Million, Adjusted EBITDA of $5.1 Billion, U.S. GAAP Net Cash Provided by Operating Activities of $2.8 Billion and Free Cash Flow of $2.4 Billion   Reports Third Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis in 2023 and Expects to see Continued Growth in 2024[2]   Immediatel ...

Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.Viatris and Idorsia will both contribute to the development costs for both programs.Includes future optionality to expand collaboration with add ...

Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance PITTSBURGH – Feb. 28, 2024 – Viatris Inc. (NASDAQ: VTRS) today announced its financial results for the fourth quarter and full year 2023. Financial Impact of Transactions and Acquired IPR&D | ($M) | 2023 Guidance Ranges | – | Divestitures and (1) Acquisitions | – | Acquired (2) IPR&D | = | 2023 Adjusted Guidance Ranges | 2023 Results | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Total Reven ...

Viatris (VTRS) , a global healthcare company, is scheduled to report fourth-quarter results on Feb 28, 2024. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.02%. In the last reported quarter, the company delivered an average surprise of 5.41%. Factors to Consider Viatris reports segmental results based on markets and geography — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ) and Greater China. The negative impact ...

Wall Street analysts forecast that Viatris (VTRS) will report quarterly earnings of $0.67 per share in its upcoming release, pointing to a year-over-year decline of 2.9%. It is anticipated that revenues will amount to $3.92 billion, exhibiting an increase of 1% compared to the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this time ...

PITTSBURGH, Feb. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for inter ...

Maca and Naca/E+ via Getty Images Viatris Inc. (NASDAQ:VTRS) is an American pharmaceutical company formed as a result of the merger of Mylan and Upjohn. The company is one of the leaders in the generics industry. Thesis Over the past two and a half months, Viatris' share price has risen more than 38%, reflecting increasing sales of its branded drugs in recent quarters, stock market euphoria about the expected Fed interest-rate cuts in 2024, and statements from its management, which anticipates the company t ...

Viatris Inc. (NASDAQ:VTRS) J.P. Morgan 42nd Annual Healthcare Conference January 10, 2024 1:30 PM ET Company Participants Scott A. Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good morning, everybody. I'm Chris Schott at J.P. Morgan. And it's my pleasure to be hosting a fireside chat today with Viatris. From the company, we're going to have a quick presentation from CEO, Scott Smith and we're going to open up to a Q&A session w ...

1 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2023 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Q3 2023 Earnings November 7, 2023 Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform A ...